Diphth,pertuss(Acell),tet Vac
Brand name: Boostrix Tdap
Rank #336 of 500 drugs by total cost
$31.2M
Total Cost
466,555
Total Claims
$31.2M
Total Cost
5,916
Prescribers
$67
Cost per Claim
464,501
Beneficiaries
467,080
30-Day Fills
$5,269
Avg Cost/Provider
79
Avg Claims/Provider
About Diphth,pertuss(Acell),tet Vac
Diphth,pertuss(Acell),tet Vac (sold as Boostrix Tdap) was prescribed 466,555 times by 5,916 Medicare Part D providers in 2023, costing the program $31.2M. At $67 per claim, this is a relatively affordable medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 333 | Rivastigmine (Rivastigmine) | $31.4M | 118,567 |
| 334 | Zolpidem Tartrate (Zolpidem Tartrate) | $31.3M | 3,144,599 |
| 335 | Lorazepam (Lorazepam) | $31.3M | 3,237,827 |
| 336 | Diphth,pertuss(Acell),tet Vac (Boostrix Tdap) | $31.2M | 466,555 |
| 337 | Tafamidis Meglumine (Vyndaqel) | $31.0M | 1,387 |
| 338 | Midodrine Hcl (Midodrine Hcl) | $30.9M | 383,390 |
| 339 | Sarilumab (Kevzara) | $30.5M | 6,822 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology